The functional roles of poly(ethylene glycol)-lipid and lysolipid in the drug retention and release from lysolipid-containing thermosensitive liposomes in vitro and in vivo.
Triggered release of liposomal contents following tumor accumulation and mild local heating is pursued as a means of improving the therapeutic index of chemotherapeutic drugs. Lysolipid-containing thermosensitive liposomes (LTSLs) are composed of dipalmitoylphosphatidylcholine (DPPC), the lysolipid monostearoylphosphatidylcholine (MSPC), and poly(ethylene glycol)-conjugated distearoylphosphatidylethanolamine (DSPE-PEG(2000)). We investigated the roles of DSPE-PEG(2000) and lysolipid in the functional performance of the LTSL-doxorubicin formulation. Varying PEG-lipid concentration (0-5 mol%) or bilayer orientation did not affect the release; however, lysolipid (0-10 mol%) had a concentration-dependent effect on drug release at 42 degrees C in vitro. Pharmacokinetics of various LTSL formulations were compared in mice with body temperature controlled at 37 degrees C. As expected, incorporation of the PEG-lipid increased doxorubicin plasma half-life; however, PEG-lipid orientation (bilayer vs. external leaflet) did not significantly improve circulation lifetime or drug retention in LTSL. Approximately 70% of lysolipid was lost within 1 h postinjection of LTSL, which could be due to interactions with the large membrane pool of the biological milieu. Considering that the present LTSL-doxorubicin formulation exhibits significant therapeutic activity when used in conjunction with mild heating, our current study provided critical insights into how the physicochemical properties of LTSL can be tailored to achieve better therapeutic activity.
Banno
Brian
B
Department of Advanced Therapeutics, BC Cancer Agency, 675 West 10th Ave., Vancouver, British Columbia, Canada V5Z1L3.
Ickenstein
Ludger M
LM
Chiu
Gigi N C
GN
Bally
Marcel B
MB
Thewalt
Jenifer
J
Brief
Elana
E
Wasan
Ellen K
EK
D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000097:blood / Q000493:pharmacokinetics; D004317:Doxorubicin / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics; D005260:Female; D008051:Lipid Bilayers / Q000097:blood / Q000737:chemistry* / Q000493:pharmacokinetics; D008081:Liposomes; D008246:Lysophospholipids / Q000097:blood / Q000737:chemistry* / Q000493:pharmacokinetics; D051379:Mice; D008815:Mice, Inbred Strains; D011092:Polyethylene Glycols / Q000737:chemistry* / Q000493:pharmacokinetics; D012995:Solubility; D013696:Temperature
D000970:Antineoplastic Agents; D008051:Lipid Bilayers; D008081:Liposomes; D008246:Lysophospholipids; D011092:Polyethylene Glycols; D004317:Doxorubicin